Indication DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

DUPIXENT PROVIDED RAPID AND SUSTAINED
IMPROVEMENT IN SENSE OF SMELL

Significantly improved UPSIT score vs placebo at Weeks 24 and 52 (secondary endpoints)1

Change in upsIt score through week 52 in trial 2
71%
Improvement

at Week 52 with DUPIXENT (baseline score 13.46) vs 6% worsening with placebo (baseline score 13.78) (LSM difference: 10.30 [95% CI: 8.50, 12.10])

  • DUPIXENT 300 mg Q2W + INCS (n=150)
  • Placebo + INCS (n=153)
67%
OF THE TOTAL IMPROVEMENT IN SENSE OF SMELL WAS SEEN AFTER THE FIRST DOSE, AS MEASURED AT WEEK 21,a
  • aChange in UPSIT score at Week 2 (LSM difference vs placebo: 5.36 [95% CI: 3.62, 7.10]).1
63%
REDUCTION IN THE NUMBER OF PATIENTS WITH ANOSMIA1,2
  • 79% (n=228/287, pooled DUPIXENT arms) of patients taking DUPIXENT 300 mg Q2W + INCS had anosmia at baseline, which was reduced to 30% (n=84/280, pooled DUPIXENT arms) at Week 24 in Trial 21,2
    • There was almost no change with placebo: 76.7% (n=115/150 total patients) of patients taking placebo + INCS had anosmia at baseline, which was reduced to 76.6% (n=111/145 total patients) at Week 24 in Trial 21,2
  • 46% IMPROVEMENT IN DAILY LOSS OF SMELL SCORE AT WEEK 52 (Trial 2: secondary endpoint) with DUPIXENT 300 mg Q2W + INCS (n=150) (-1.29 from a baseline score of 2.81) vs 7% improvement with placebo + INCS (n=153) (-0.19 from a baseline score of 2.72) (LSM difference: -1.10 [95% CI: -1.31, -0.89])1
  • University of Pennsylvania Smell Identification Test (UPSIT) score (range 0 to 40): higher score indicates improvement.
  • INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks.

Identify CRSwNP
patients appropriate
for DUPIXENT

View Patients

References:

  1. Data on file, Sanofi US. LIBERTY NP SINUS-52, CSR. 2018.
  2. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650.